By Colin Kellaher
Clarivate inked a deal to sell its life-sciences and healthcare segment to investment firm Altaris for $600 million.
Clarivate on Monday said the move will allow the London provider of global information, analytics and workflow solutions to focus on AI-driven intelligence for its academia and government and intellectual-property segments.
Clarivate said it will receive $500 million in cash at closing, along with $25 million in cash deferred to the completion of a transition-services agreement and a $75 million seller note, adding that it plans to use the cash proceeds to pare its debt load and bolster its balance sheet.
The company said it expects to complete the sale by the end of the year, and that it expects to book a non-cash goodwill impairment of $225 million to $250 million on the life-sciences and healthcare segment.
Altaris, a New York firm that focuses exclusively on the healthcare industry and manages more than $9 billion of equity capital, last month agreed to buy drug-development company Simulations Plus for around $375 million.
Write to Colin Kellaher at colin.kellaher@wsj.com